Scarica l'app Stockscreener
123.46
2.56%
3.08
Dopo l'orario di chiusura:
123.46
Palvella Therapeutics Inc Borsa (PVLA) Ultime notizie
Palvella appoints McDonough as SVP of market access, patient services - msn.com
Breakout Move: What makes Palvella Therapeutics Inc stock attractive today2026 Selloffs & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Palvella Appoints McDonough as SVP of Market Access, Patient Services - MyChesCo
Can Palvella Therapeutics Inc lead its sector in growthPortfolio Update Summary & Safe Entry Zone Identification - baoquankhu1.vn
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - marketbeat.com
Palvella Therapeutics, Inc. (PVLA) stock price, news, quote and history - Yahoo Finance UK
Rare disease breakthrough? Palvella reports strong phase 2 results - msn.com
HC Wainwright Brokers Decrease Earnings Estimates for PVLA - marketbeat.com
Lifesci Capital Brokers Decrease Earnings Estimates for PVLA - marketbeat.com
What is HC Wainwright's Estimate for PVLA Q1 Earnings? - marketbeat.com
Palvella Therapeutics (PVLA) price target increased by 15.78% to 224.97 - msn.com
Palvella’s Phase III Success And Fast Track Status Test Current Valuation - Yahoo Finance
Mizuho reiterates Palvella Therapeutics stock rating on pipeline By Investing.com - Investing.com Canada
Chardan Raises Price Target on Palvella Therapeutics to $240 From $210, Keeps Buy Rating - MarketScreener
US Stocks Recap: What makes Palvella Therapeutics Inc stock attractive todayEarnings Overview Summary & Daily Stock Trend Reports - baoquankhu1.vn
Palvella Hire Highlights QTORIN Launch Plans And Deep Rare Skin Focus - Sahm
Chardan raises Palvella stock price target to $240 on pipeline progress - Investing.com Canada
Palvella Therapeutics (NASDAQ:PVLA) Price Target Raised to $240.00 - MarketBeat
Palvella Highlights 2025 Results and SELVA Phase 3 Progress - TipRanks
Oppenheimer raises Palvella Therapeutics price target on valuation By Investing.com - Investing.com India
Stifel reiterates Buy rating on Palvella stock, $250 target By Investing.com - Investing.com Canada
Oppenheimer raises Palvella Therapeutics price target on valuation - Investing.com
Palvella Therapeutics Announces Positive Phase 3 Results for QTORIN Rapamycin, Prepares NDA Submission and U.S. Launch for Rare Skin Disease Therapies - Minichart
Palvella Therapeutics, Inc. (PVLA) Reports FY2025 Earnings - AlphaStreet
Palvella Therapeutics Q4 2025 Earnings Call Transcript - marketbeat.com
Palvella Therapeutics (NASDAQ:PVLA) Trading 14.4% HigherShould You Buy? - MarketBeat
PVLA: Positive phase III data, pipeline expansion, and $230M financing position for 2026 NDA submission - TradingView
PALVELLA THERAPEUTICS ($PVLA) Releases Q4 2025 Earnings, Stock Rises - Quiver Quantitative
PVLA: Positive phase III data, pipeline growth, and $230M financing position for 2027 FDA approval - TradingView
Palvella Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Palvella Therapeutics QTORIN Rapamycin: Novel Treatment Advancements for Rare Skin Diseases and Vascular Malformations - Minichart
Palvella Therapeutics Q4 Earnings Call Highlights - marketbeat.com
Earnings call transcript: Palvella Therapeutics’ Q4 2025 results showcase strong clinical progress - Investing.com
European Patent Office grants Palvella patent for QTORIN rapamycin - MSN
Palvella Therapeutics (NASDAQ:PVLA) Issues Quarterly Earnings Results, Misses Expectations By $0.13 EPS - marketbeat.com
OS Therapies Incorporated (OSTX) Reports FY2025 Earnings - AlphaStreet
Palvella 10-K: $0 Revenue, Net Loss $41.7M — Operating Loss $38.6M - TradingView
Palvella Therapeutics (NASDAQ: PVLA) leans on QTORIN data in rare skin diseases - Stock Titan
Palvella (NASDAQ: PVLA) wins Phase 3 QTORIN data and $230M raise - Stock Titan
Palvella Therapeutics reports full year 2025 financial results and provides corporate update - marketscreener.com
Palvella Therapeutics Reports Full Year 2025 Financial Results And Provides Corporate Update - TradingView
Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update - The Manila Times
Palvella Therapeutics: Q4 Earnings Snapshot - Barchart
Earnings Flash (PVLA) Palvella Posts 2025 Loss $3.71 a Share, vs. FactSet Est of $3.57 Loss - MarketScreener
Palvella announces publication on lymphatic malformation subtypes By Investing.com - Investing.com South Africa
How does Palvella Therapeutics Inc compare to its peersMarket Growth Report & Verified Entry Point Signals - baoquankhu1.vn
Palvella Therapeutics Highlights Continued Progress across Rare Skin Disease Pipeline with Two Poster Presentations at the 2026 American Academy of Dermatology Annual Meeting - MarketScreener
Palvella Therapeutics Announces Scientific Publication in Journal of Vascular Anomalies Highlighting the Infiltrative Growth and Therapeutic Challenges of Microcystic Lymphatic Malformations - Bitget
Palvella announces publication on lymphatic malformation subtypes - Investing.com
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):